Shares of Southwestern Energy Company (NYSE:SWN) ended -1.19% lower at $5.83. Nearly 15.75 million shares were traded by the close, lower than its average daily volume of 15.94 million shares.
Southwestern Energy Company (SWN) Analyst Opinion
Southwestern Energy Company has a consensus hold rating from 34 Wall Street analysts, and the number of shares currently sold short amount to at least 7.89% of shares outstanding. The stock spiked 7.76% last month and is down -46.12 this year. Wall Street is only getting more bullish on the stock, with 10 of analysts who cover SWN having a buy-equivalent rating. Analysts have placed a $8.36 price target on Southwestern Energy Company, suggesting a 43.4% gain from recent close. It’s currently trading about -59.46% below its 52-week high.
Southwestern Energy Company Earnings Surprise
Southwestern Energy Company (SWN) failed to surprise the stock market in its last reported earnings when it earned $0.08 a piece versus the consensus-estimated $0.15. Its revenue totaled $806.32 million down -4.69% from the previous quarter.
Southwestern Energy Company (NYSE:SWN) Intraday View
This stock (SWN) is ahead of its 52-week low with 16.6%. Its last month’s stock price volatility remained 3.62% which for the week stands at 4.13%. The share price has moved backward from its 20 days moving average, trading at a distance of -3.42% and stays 3.57% away from its 50 days moving average. Over the last five days, shares have faced -6.87% losses and now is down -18.52% since hitting its 200-day moving average of $6.34. Southwestern Energy Company (SWN) has made its way to a 12-month decline of -57.48%.
Turning to BioLine Rx Ltd (NASDAQ:BLRX), its shares were trading at $1.25 a retreat of $0, on the trading floor. The stock, after opening at $1.24, touched a high of $1.27 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.8. BioLine Rx Ltd has 1 buy ratings, 0 holds and 0 sells even after the stock tumbled -9.06% from its high of $1.38 to a $120 million market value through last close.
BioLine Rx Ltd (BLRX) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 1.75 to 1.75 during a month. Analysts set a 12-month price target of $3.25 a share. The target implies a 160% spike from where the shares are currently trading. Also, the current price highlights a discount of 220% to analysts’ high consensus price target.
BioLine Rx Ltd (NASDAQ:BLRX) Intraday Trading
The counter witnessed a trading volume of 0.32 million shares versus an average volume of 0.63 million shares during last trading session. Its last month’s stock price volatility remained 6.75% which for the week approaches 5.63%. The lowest price the stock reached in the last trading day was $1.21 and compares with the $0.801 52-week low. The stock recovered 56.68% since its low point and has performed 36.41% year-to-date.